Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2019

View Archived Issues

AVPR1A is a new therapeutic target for castration-resistant prostate cancer

Researchers review the potential of integrating 4D printing with nanomedicine

Allergan is recruiting participants in phase I/II study of AGN-151587 in patients with LCA10

Enrollment ongoing in phase I study of NGM-621

Novartis initiates phase I study of DKY-709 alone or in combination with PDR-001

Identification of plasma and antibody glycomic biomarkers to predict time to HIV rebound

ViiV Healthcare presents week 96 data from ongoing phase III BRIGHTE study

Phase I data on Arcus Biosciences' AB-928 support trials in cancer patients

Evaluation of novel noninvasive ADXBLADDER test to detect bladder cancer

Polymersome delivery reduces side effects, enhances islet transplantation with rapamycin

Enzyme may be important therapeutic fibrosis target

NOX4 targeting potentially suppresses epithelial-mesenchymal transition in RPE

Insights into frequent NSCLC mutation

G1 Therapeutics divulges new cyclin-dependent kinases inhibitors

Seal Rock Therapeutics patents MAP3K5 inhibitors

Adamed presents new MDM2 inhibitors

Sichuan Kelun-Biotech Biopharmaceutical synthesizes new antivirals

New ketamine prodrugs presented by XW Laboratories

IDMC recommends continuation of PROLONG trial of OBE-022 in preterm labor

Sanofi announces topline phase III data on Zynquista, provides notice to end Lexicon collaboration

PARAGON-HF study of sacubitril/valsartan misses statistical significance on primary endpoint

Hoxb8-mutated mice develop OCD-like behavior and chronic anxiety

FDA approves Accrufer for iron deficiency in adults

Adaptimmune begins SPEARHEAD-1 trial with ADP-A2M4 SPEAR T cells

FDA clears IND for EPX-100 for Dravet syndrome